GRIFOLS S A/S (NASDAQ:GRFS) Downgraded by Zacks Investment Research to “Sell”

Zacks Investment Research cut shares of GRIFOLS S A/S (NASDAQ:GRFS) from a hold rating to a sell rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

A number of other brokerages have also recently weighed in on GRFS. JPMorgan Chase & Co. cut Sogou from a neutral rating to an underweight rating and dropped their price target for the stock from $5.50 to $4.12 in a research report on Thursday, June 27th. BidaskClub cut Vertex Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday. Three analysts have rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $20.75.

NASDAQ:GRFS traded down $0.16 during trading hours on Wednesday, reaching $21.66. 515,915 shares of the stock were exchanged, compared to its average volume of 1,110,831. The company has a quick ratio of 1.13, a current ratio of 2.87 and a debt-to-equity ratio of 1.41. The company’s 50 day moving average is $19.62. GRIFOLS S A/S has a 52 week low of $17.42 and a 52 week high of $21.99. The firm has a market cap of $14.90 billion, a PE ratio of 18.51, a P/E/G ratio of 1.30 and a beta of 1.16.

GRIFOLS S A/S (NASDAQ:GRFS) last released its earnings results on Tuesday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, hitting analysts’ consensus estimates of $0.25. GRIFOLS S A/S had a return on equity of 15.49% and a net margin of 12.35%. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. Research analysts predict that GRIFOLS S A/S will post 1.27 earnings per share for the current year.

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, June 18th. Stockholders of record on Monday, June 10th were given a dividend of $0.14 per share. The ex-dividend date of this dividend was Friday, June 7th. GRIFOLS S A/S’s payout ratio is 22.22%.

Several institutional investors have recently made changes to their positions in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of GRIFOLS S A/S by 9.1% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,296 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 526 shares during the period. Advisors Asset Management Inc. raised its position in shares of GRIFOLS S A/S by 40.8% during the 1st quarter. Advisors Asset Management Inc. now owns 5,108 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 1,479 shares during the period. Lenox Wealth Management Inc. raised its position in shares of GRIFOLS S A/S by 0.7% during the 1st quarter. Lenox Wealth Management Inc. now owns 236,947 shares of the biotechnology company’s stock worth $4,765,000 after purchasing an additional 1,652 shares during the period. Bank of Montreal Can raised its position in shares of GRIFOLS S A/S by 2.3% during the 1st quarter. Bank of Montreal Can now owns 89,850 shares of the biotechnology company’s stock worth $1,807,000 after purchasing an additional 2,017 shares during the period. Finally, Quadrant Capital Group LLC increased its position in GRIFOLS S A/S by 15.6% in the 1st quarter. Quadrant Capital Group LLC now owns 16,291 shares of the biotechnology company’s stock valued at $318,000 after acquiring an additional 2,193 shares during the period. Institutional investors and hedge funds own 19.01% of the company’s stock.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

See Also: Systematic Risk

Get a free copy of the Zacks research report on GRIFOLS S A/S (GRFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.